Skip to main content
Journal cover image

Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.

Publication ,  Journal Article
Sanders, GD; Kong, MH; Al-Khatib, SM; Peterson, ED
Published in: Am Heart J
July 2010

BACKGROUND: More than 80% of sudden cardiac deaths (SCDs) occur in patients >or=65 years old; the cost-effectiveness of implantable cardioverter defibrillator (ICD) therapy in older patients remains unclear. We sought to examine the cost-effectiveness of ICD therapy in at-risk patients >or=65 years old. METHODS: We developed a Markov model to evaluate lifetime costs and benefits of ICD therapy compared with optimal medical therapy in patients >or=65 years of age with left ventricular dysfunction. Data were derived from the literature and existing clinical trials of primary prevention of SCD. Outcome measures included life years, quality-adjusted life years, costs, and incremental cost-effectiveness. RESULTS: Benefits and costs of ICD therapy in older individuals varied widely by clinical-trial population. In the 5 trials considered, for patients >or=65 years of age, ICDs demonstrated a life expectancy benefit compared with control therapy (incremental cost-effectiveness ratios ranging from $37,031-$138,458 per quality-adjusted life year). For 75-year-old patients, the findings were qualitatively similar, although cost-effectiveness was reduced in all trial populations. In sensitivity analyses, cost-effectiveness of ICD therapy in older individuals depended upon the trial population, quality of life, device cost, and frequency of generator replacement. Sensitivity analyses on other variables did not change the results substantially. CONCLUSIONS: The cost-effectiveness of ICD therapy for primary prevention in older patients varies widely among trials. Given an aging US population and the high risk of SCD in these individuals, further studies of ICD therapy and their cost-effectiveness-specifically in older patients-are needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

July 2010

Volume

160

Issue

1

Start / End Page

122 / 131

Location

United States

Related Subject Headings

  • United States
  • Quality of Life
  • Prognosis
  • Primary Prevention
  • Male
  • Humans
  • Heart Failure
  • Female
  • Defibrillators, Implantable
  • Death, Sudden, Cardiac
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sanders, G. D., Kong, M. H., Al-Khatib, S. M., & Peterson, E. D. (2010). Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J, 160(1), 122–131. https://doi.org/10.1016/j.ahj.2010.04.021
Sanders, Gillian D., Melissa H. Kong, Sana M. Al-Khatib, and Eric D. Peterson. “Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.Am Heart J 160, no. 1 (July 2010): 122–31. https://doi.org/10.1016/j.ahj.2010.04.021.
Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J. 2010 Jul;160(1):122–31.
Sanders, Gillian D., et al. “Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.Am Heart J, vol. 160, no. 1, July 2010, pp. 122–31. Pubmed, doi:10.1016/j.ahj.2010.04.021.
Sanders GD, Kong MH, Al-Khatib SM, Peterson ED. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Am Heart J. 2010 Jul;160(1):122–131.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

July 2010

Volume

160

Issue

1

Start / End Page

122 / 131

Location

United States

Related Subject Headings

  • United States
  • Quality of Life
  • Prognosis
  • Primary Prevention
  • Male
  • Humans
  • Heart Failure
  • Female
  • Defibrillators, Implantable
  • Death, Sudden, Cardiac